PMC:7242013 / 13703-13986
Annnotations
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T44 | 141-149 | Body_part | denotes | tyrosine | http://purl.org/sig/ont/fma/fma82768 |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
420 | 124-127 | Gene | denotes | HCC | Gene:619501 |
421 | 24-27 | Gene | denotes | HCC | Gene:619501 |
425 | 80-88 | Species | denotes | patients | Tax:9606 |
426 | 221-229 | Species | denotes | patients | Tax:9606 |
427 | 141-156 | Gene | denotes | tyrosine kinase | Gene:7294 |
428 | 94-102 | Disease | denotes | COVID‐19 | MESH:C000657245 |
429 | 235-243 | Disease | denotes | COVID‐19 | MESH:C000657245 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T171 | 24-27 | Disease | denotes | HCC | http://purl.obolibrary.org/obo/MONDO_0007256 |
T172 | 94-102 | Disease | denotes | COVID‐19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T173 | 124-127 | Disease | denotes | HCC | http://purl.obolibrary.org/obo/MONDO_0007256 |
T174 | 235-243 | Disease | denotes | COVID‐19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T56 | 141-167 | Chemical | denotes | tyrosine kinase inhibitors | http://purl.obolibrary.org/obo/CHEBI_38637 |
T57 | 141-149 | Chemical | denotes | tyrosine | http://purl.obolibrary.org/obo/CHEBI_18186 |
T58 | 157-167 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
T59 | 189-199 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
LitCovid-PD-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T5 | 150-167 | http://purl.obolibrary.org/obo/GO_0033673 | denotes | kinase inhibitors |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T150 | 0-283 | Sentence | denotes | It is uncertain whether HCC treatment should be deferred or started as usual in patients with COVID‐19 with newly diagnosed HCC, and whether tyrosine kinase inhibitors (TKIs) or checkpoint inhibitors should be stopped in patients with COVID‐19 who are already receiving such therapy. |